CARsgen's Zevor-cel, a BCMA-Targeted CAR-T Therapy, Included in China's 2025 Innovative Drug Catalogue

CARsgen Therapeutics Holdings Limited has announced that its fully human BCMA-targeted CAR T-cell therapy, zevorcabtagene autoleucel (zevor-cel), is now included in China's 2025 Commercial Health Insurance Innovative Drug Catalogue. This catalogue, established by the National Healthcare Security Administration (NHSA), supports highly innovative drugs with significant clinical value to enhance accessibility. Zevor-cel, approved by China's National Medical Products Administration in February 2024, is indicated for adults with relapsed or refractory multiple myeloma after at least three prior treatments. CARsgen has partnered with Huadong Medicine for exclusive commercial rights in mainland China, with orders in 2025 surpassing the previous year. Clinical data show zevor-cel demonstrates deep, durable efficacy and a manageable safety profile with no severe neurotoxicities or cytokine release syndrome observed. Its inclusion in the innovative drug catalogue aims to reduce patient financial burden and improve access to advanced cell therapies. CARsgen continues to develop differentiated CAR T-cell products with a focus on safety, efficacy, and cost reduction, supporting China's health initiatives and global biopharmaceutical development.